SEARCH

Current Edition

AstraZeneca

AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche

Dive Brief: The Food and Drug Administration approved the antibody treatment Enhertu for earlier use in breast cancer patients, the latest milestone for a drug …

Continue Reading →
AstraZeneca

AstraZeneca, Daiichi press rivals with new results for breast cancer drug

Dive Brief: AstraZeneca and Daiichi Sankyo’s antibody drug Enhertu could become standard treatment for a large group of breast cancer patients following Phase 3 study …

Continue Reading →
acquires

Daiichi acquires another ADC drug through Glycotope licensing deal

Daiichi Sankyo is bringing a seventh antibody-drug conjugate, or ADC, into its pipeline through a licensing agreement with German biotech Glycotope. Specific financials weren’t disclosed, …

Continue Reading →